# Mucopolysaccharidosis Type III (Sanfilippo Syndrome): Developing Drugs for Treatment Guidance for Industry: Draft Guidance for Industy - FDA Guidance Document

Source: https://www.globalkeysolutions.net/guidances/guidance-document/mucopolysaccharidosis-type-iii-sanfilippo-syndrome-developing-drugs-for-treatment-guidance-for-industry-draft-guidance-for-industy/942f35fd-9db0-4292-9bf9-3ebc347373df

> FDA guidance document: Mucopolysaccharidosis Type III (Sanfilippo Syndrome): Developing Drugs for Treatment Guidance for Industry: Draft Guidance for Industy. Issue date: February 04, 2020. Get complete insights and analysis.

---

## Details

- Title: Mucopolysaccharidosis Type III (Sanfilippo Syndrome): Developing Drugs for Treatment Guidance for Industry: Draft Guidance for Industy
- Communication Type: Guidance Document
- Product Type: biologics
- Office Name: Center for Drug Evaluation and Research
- Office URL: /offices/center-for-drug-evaluation-and-research/cd980d74-1cbf-4226-ba9a-9045324c236c
- Issue Date: 2020-02-04
- Comment Close Date: 2020-05-05
- Last Changed: 2020-05-14
- Docket Number: <a href="https://www.regulations.gov/docket/FDA-2019-D-5404">FDA-2019-D-5404</a>

## Related Documents

- [Treatment for Heart Failure: Endpoints for Drug Development Guidance for Industry](https://www.globalkeysolutions.net/guidances/guidance-document/treatment-for-heart-failure-endpoints-for-drug-development-guidance-for-industry/3a3c4b6b-8dd2-4027-b7e6-10f7059fe28b)
- [Neovascular Age-Related Macular Degeneration: Developing Drugs for Treatment](https://www.globalkeysolutions.net/guidances/guidance-document/neovascular-age-related-macular-degeneration-developing-drugs-for-treatment/3b32c08c-4e69-42f4-ba19-cda20a8af050)
- [Fabry Disease: Developing Drugs for Treatment Guidance for Industry](https://www.globalkeysolutions.net/guidances/guidance-document/fabry-disease-developing-drugs-for-treatment-guidance-for-industry/37d2e0fe-939f-490c-8fec-d2753a0f2f8c)